A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...
Zacks.com on MSN2d
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY GainsAbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...
AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.
For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...
AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of ...
Like most major biotech players, Abbvie eyed M&A as a major strategy to build out its pipeline and chart a future. And ...
Shares of AbbVie plunged, losing more than 12% of their value after the drugmaker said participants in two mid-stage trials of its experimental schizophrenia drug, emraclidine, showed no significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback